The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Hereditary Breast Cancer: The Era of New Susceptibility Genes
Open accessAbstract
Breast cancer is the most common malignancy among females. 5%–10% of breast cancer cases are hereditary and are caused by pathogenic mutations in the considered reference BRCA1 and BRCA2 genes. As sequencing technologies evolve, more susceptible genes have been discovered and BRCA1 and BRCA2 predisposition seems to be only a part of the story. These new findings include rare germline mutations in other high penetrant genes, the most important of which include TP53 mutations in Li-Fraumeni syndrome,STK11 mutations in Peutz-Jeghers syndrome, and PTEN mutations in Cowden syndrome. Furthermore, more frequent, but less penetrant, mutations have been identified in families with breast cancer clustering, in moderate or low penetrant genes, such as CHEK2,ATM,PALB2,and BRIP1. This paper will summarize all current data on new findings in breast cancer susceptibility genes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,071
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography
Saslow, D., Boetes, C., Burke, W., Harms, S., Leach, M. O., Lehman, C. D., Morris, E., Pisano, E., Schnall, M., Sener, S., et al. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.2.75 · Cited by 2,637
Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21
Hall, J. M., Lee, M. K., Newman, B., Morrow, J. E., Anderson, L. A., Huey, B., & King, M.-C. (1990) · Science · doi:10.1126/science.2270482 · Cited by 2,550
Genome-wide association study identifies novel breast cancer susceptibility loci
Easton, D. F., Pooley, K. A., Dunning, A. M., Pharoah, P. D. P., Thompson, D., Ballinger, D. G., Struewing, J. P., Morrison, J., Field, H., Luben, R., et al. (2007) · Nature · doi:10.1038/nature05887 · Cited by 2,319
Estimates of cancer incidence and mortality in Europe in 2008
Ferlay, J., Parkin, D. M., & Steliarova-Foucher, E. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.014 · Cited by 2,319
Listening to silence and understanding nonsense: exonic mutations that affect splicing
Cartegni, L., Chew, S. L., & Krainer, A. R. (2002) · Nature Reviews Genetics · doi:10.1038/nrg775 · Cited by 2,209
ESEfinder: a web resource to identify exonic splicing enhancers
Cartegni, L. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg616 · Cited by 1,603
Cancer Risks in BRCA2 Mutation Carriers
Breast Cancer Linkage Consortium, T. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1310 · Cited by 1,527
Hunter, D. J., Kraft, P., Jacobs, K. B., Cox, D. G., Yeager, M., Hankinson, S. E., Wacholder, S., Wang, Z., Welch, R., Hutchinson, A., et al. (2007) · Nature Genetics · doi:10.1038/ng2075 · Cited by 1,481
Very high risk of cancer in familial Peutz–Jeghers syndrome
Giardiello, F. M., Brensinger, J. D., Tersmette, A. C., Goodman, S. N., Petersen, G. M., Booker, S. V., Cruz–Correa, M., & Offerhaus, J. A. (2000) · Gastroenterology · doi:10.1053/gast.2000.20228 · Cited by 1,445
Risk-Reducing Salpingo-oophorectomy in Women with a BRCA1 or BRCA2 Mutation
Kauff, N. D., Satagopan, J. M., Robson, M. E., Scheuer, L., Hensley, M., Hudis, C. A., Ellis, N. A., Boyd, J., Borgen, P. I., Barakat, R. R., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020119 · Cited by 1,251
Wang, Y., Cortez, D., Yazdi, P., Neff, N., Elledge, S. J., & Qin, J. (2000) · Genes & Development · doi:10.1101/gad.14.8.927 · Cited by 1,221 · cited 1×
“The encoded protein combines with other tumour suppressors, DNA damage sensors, and signal transducers to form a large multisubunit protein complex, known as the BRCA1-associated genome surveillance complex [10].”
Rebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., van ’t Veer, L., Garber, J. E., Evans, G. R., Narod, S. A., Isaacs, C., Matloff, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.188 · Cited by 1,171 · cited 1×
“Prophylactic surgeries that include bilateral mastectomy and salpingo-oophorectomy can significantly reduce mortality in these patients [27, 28].”
Sorting out the complexity of SR protein functions
GRAVELEY, B. R. (2000) · RNA · doi:10.1017/s1355838200000960 · Cited by 1,078
Regulation of Homologous Recombination in Eukaryotes
Heyer, W.-D., Ehmsen, K. T., & Liu, J. (2010) · Annual Review of Genetics · doi:10.1146/annurev-genet-051710-150955 · Cited by 1,066
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene
The Breast Cancer Susceptibility Collaboration (UK), Rahman, N., Seal, S., Thompson, D., Kelly, P., Renwick, A., Elliott, A., Reid, S., Spanova, K., Barfoot, R., et al. (2007) · Nature Genetics · doi:10.1038/ng1959 · Cited by 1,003
BRCA1 and BRCA2: 1994 and beyond
Narod, S. A., & Foulkes, W. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1431 · Cited by 967
Genetic analysis of breast cancer in the cancer and steroid hormone study.
Claus, E. B., RISCH, N. J., & Thompson, W. D. (1991) · PubMed · Cited by 911
Frequency and Spectrum of Cancers in the Peutz-Jeghers Syndrome
Hearle, N., Schumacher, V., Menko, F. H., Olschwang, S., Boardman, L. A., Gille, J. J. P., Keller, J. J., Westerman, A. M., Scott, R. J., Lim, W., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0083 · Cited by 855
Increased Risk of Cancer in the Peutz–Jeghers Syndrome
Giardiello, F. M., Welsh, S. B., Hamilton, S. R., Offerhaus, G. J. A., Gittelsohn, A. M., Booker, S. V., Krush, A. J., Yardley, J. H., & Luk, G. D. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706113162404 · Cited by 848
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
Jones, S., Hruban, R. H., Kamiyama, M., Borges, M., Zhang, X., Parsons, D. W., Lin, J. C.-H., Palmisano, E., Brune, K., Jaffee, E. M., et al. (2009) · Science · doi:10.1126/science.1171202 · Cited by 826 · cited 1×
“Familial pancreatic and/or breast cancer due to PALB2 mutations is inherited in an autosomal dominant pattern, while Fanconi anaemia is an autosomal recessive condition [82, 83].”
Peutz–Jeghers syndrome: a systematic review and recommendations for management
Beggs, A. D., Latchford, A. R., Vasen, H. F. A., Moslein, G., Alonso, A., Aretz, S., Bertario, L., Blanco, I., Bülow, S., Burn, J., et al. (2010) · Gut · doi:10.1136/gut.2009.198499 · Cited by 824
Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2
Roa, B. B., Boyd, A. A., Volcik, K., & Richards, C. S. (1996) · Nature Genetics · doi:10.1038/ng1096-185 · Cited by 770
The Breast Cancer Susceptibility Collaboration (UK), Seal, S., Thompson, D., Renwick, A., Elliott, A., Kelly, P., Barfoot, R., Chagtai, T., Jayatilake, H., Ahmed, M., et al. (2006) · Nature Genetics · doi:10.1038/ng1902 · Cited by 746 · cited 1×
“In 2006, truncatingmutationswere identified in breast cancer families [95], while the relative breast cancer risk, although there are reports of higher risks in some families, was estimated around 2.”
Lakhani, S. R., Jacquemier, J., Sloane, J. P., Gusterson, B. A., Anderson, T. J., van de Vijver, M. J., Farid, L. M., Venter, D., Antoniou, A., Storfer-Isser, A., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.15.1138 · Cited by 707
Hereditary Cancer Predisposition Syndromes
Garber, J. E., & Offit, K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.042 · Cited by 697
Abraxas and RAP80 Form a BRCA1 Protein Complex Required for the DNA Damage Response
Wang, B., Matsuoka, S., Ballif, B. A., Zhang, D., Smogorzewska, A., Gygi, S. P., & Elledge, S. J. (2007) · Science · doi:10.1126/science.1139476 · Cited by 695
Yang, X. R., Chang-Claude, J., Goode, E. L., Couch, F. J., Nevanlinna, H., Milne, R. L., Gaudet, M., Schmidt, M. K., Broeks, A., Cox, A., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq526 · Cited by 691
Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases
Blencowe, B. J. (2000) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)01549-8 · Cited by 689
Spectrum of Mutations in BRCA1, BRCA2, CHEK2, and TP53 in Families at High Risk of Breast Cancer
Walsh, T., Casadei, S., Coats, K. H., Swisher, E., Stray, S. M., Higgins, J., Roach, K. C., Mandell, J., Lee, M. K., Ciernikova, S., et al. (2006) · JAMA · doi:10.1001/jama.295.12.1379 · Cited by 666
BRCA1 and BRCA2 and the genetics of breast and ovarian cancer
Welcsh, P. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.705 · Cited by 648
Pharoah, P. D. P., Guilford, P., & Caldas, C. (2001) · Gastroenterology · doi:10.1053/gast.2001.29611 · Cited by 638
The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability
Gudmundsdottir, K., & Ashworth, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209874 · Cited by 622
A common coding variant in CASP8 is associated with breast cancer risk
The Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer, Cox, A., on behalf of the Breast Cancer Association Consortium, Dunning, A. M., Garcia-Closas, M., Balasubramanian, S., Reed, M. W. R., Pooley, K. A., Scollen, S., Baynes, C., et al. (2007) · Nature Genetics · doi:10.1038/ng1981 · Cited by 610
Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations
Gonzalez, K. D., Noltner, K. A., Buzin, C. H., Gu, D., Wen-Fong, C. Y., Nguyen, V. Q., Han, J. H., Lowstuter, K., Longmate, J., Sommer, S. S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6959 · Cited by 609
Olivier, M., Goldgar, D. E., Sodha, N., Ohgaki, H., Kleihues, P., Hainaut, P. L., & Eeles, R. A. (2003) · PubMed · Cited by 576
Will the real Cowden syndrome please stand up: revised diagnostic criteria
Eng, C. (2000) · Journal of Medical Genetics · doi:10.1136/jmg.37.11.828 · Cited by 566
CHEK2 Is a Multiorgan Cancer Susceptibility Gene
Cybulski, C., Górski, B., Huzarski, T., Masojć, B., Mierzejewski, M., Dębniak, T., Teodorczyk, U., Byrski, T., Gronwald, J., Matyjasik, J., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/426403 · Cited by 551
The Cowden syndrome: a clinical and genetic study in 21 patients
Starink, T. M., Veen, J. P. W. V. D., Arwert, F., Waal, L. P. D., Lange, G. G. D., Gille, J. J. P., & Eriksson, A. W. (1986) · Clinical Genetics · doi:10.1111/j.1399-0004.1986.tb00816.x · Cited by 550
Cancer Risks and Mortality in Heterozygous ATM Mutation Carriers
Thompson, D., Duedal, S., Kirner, J., McGuffog, L., Last, J., Reiman, A., Byrd, P., Taylor, M., & Easton, D. F. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji141 · Cited by 543
High Cancer Risk in Peutz–Jeghers Syndrome: A Systematic Review and Surveillance Recommendations
van Lier, M. G. F., Wagner, A., Mathus-Vliegen, E. M. H., Kuipers, E. J., Steyerberg, E. W., & van Leerdam, M. E. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.725 · Cited by 542
Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1
Zheng, W., Long, J., Gao, Y.-T., Li, C., Zheng, Y., Xiang, Y.-B., Wen, W., Levy, S., Deming, S. L., Haines, J. L., et al. (2009) · Nature Genetics · doi:10.1038/ng.318 · Cited by 541
Thomas, G., Jacobs, K. B., Kraft, P., Yeager, M., Wacholder, S., Cox, D. G., Hankinson, S. E., Hutchinson, A., Wang, Z., Yu, K., et al. (2009) · Nature Genetics · doi:10.1038/ng.353 · Cited by 536
Germline mutations in RAD51D confer susceptibility to ovarian cancer
Breast Cancer Susceptibility Collaboration (UK), Loveday, C., Turnbull, C., Ramsay, E., Hughes, D., Ruark, E., Frankum, J. R., Bowden, G., Kalmyrzaev, B., Warren-Perry, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.893 · Cited by 534
Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study
Canto, M. I., Goggins, M., Hruban, R. H., Petersen, G. M., Giardiello, F. M., Yeo, C., Fishman, E. K., Brune, K., Axilbund, J., Griffin, C., et al. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.02.005 · Cited by 524
Newman, B., Austin, M. A., Lee, M., & King, M. C. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.9.3044 · Cited by 515
Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations
Fackenthal, J. D., & Olopade, O. I. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2054 · Cited by 488
Walsh, T., Lee, M. K., Casadei, S., Thornton, A. M., Stray, S. M., Pennil, C., Nord, A. S., Mandell, J. B., Swisher, E. M., & King, M.-C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007983107 · Cited by 487
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2
SEARCH, Ahmed, S., The GENICA Consortium, kConFab, Australian Ovarian Cancer Study Group, Thomas, G., Ghoussaini, M., Healey, C. S., Humphreys, M. K., Platte, R., et al. (2009) · Nature Genetics · doi:10.1038/ng.354 · Cited by 477
(2004) · The American Journal of Human Genetics · doi:10.1086/421251 · Cited by 471
Founder and Recurrent CDH1 Mutations in Families With Hereditary Diffuse Gastric Cancer
Kaurah, P., MacMillan, A., Boyd, N., Senz, J., De Luca, A., Chun, N., Suriano, G., Zaor, S., Van Manen, L., Gilpin, C., et al. (2007) · JAMA · doi:10.1001/jama.297.21.2360 · Cited by 447
PI 3-kinase related kinases: ‘big’ players in stress-induced signaling pathways
Abraham, R. T. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.04.002 · Cited by 440
Ataxia–telangiectasia, an evolving phenotype
Chun, H. H., & Gatti, R. A. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.04.010 · Cited by 428
Mutation of the RAD51C gene in a Fanconi anemia–like disorder
Vaz, F., Hanenberg, H., Schuster, B., Barker, K., Wiek, C., Erven, V., Neveling, K., Endt, D., Kesterton, I., Autore, F., et al. (2010) · Nature Genetics · doi:10.1038/ng.570 · Cited by 408 · cited 1×
“RAD51C is an essential gene in homologous recombination, while biallelic missense mutations in the gene cause a Fanconi anemia-like phenotype [98].”
Mutations in BRIP1 confer high risk of ovarian cancer
Rafnar, T., Gudbjartsson, D. F., Sulem, P., Jonasdottir, A., Sigurdsson, A., Jonasdottir, A., Besenbacher, S., Lundin, P., Stacey, S. N., Gudmundsson, J., et al. (2011) · Nature Genetics · doi:10.1038/ng.955 · Cited by 406
(2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1167 · Cited by 372
Brooks-Wilson, A. R., Kaurah, P., Suriano, G., Leach, S., Senz, J., Grehan, N., Butterfield, Y. S. N., Jeyes, J., Schinas, J., Bacani, J., et al. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.018275 · Cited by 361
Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers.
Nichols, K. E., Malkin, D. M., Garber, J. E., Fraumeni, J. F., & Li, F. P. (2001) · PubMed · Cited by 354
Population-based study of risk of breast cancer in carriers of BRCA2 mutation
Thorlacius, S., Struewing, J. P., Hartage, P., Olafsdottir, G. H., Sigvaldason, H., Tryggvadottir, L., Wacholder, S., Tulinius, H., & Eyfjörd, J. E. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03300-5 · Cited by 348
Tomlinson, I. P., & Houlston, R. S. (1997) · Journal of Medical Genetics · doi:10.1136/jmg.34.12.1007 · Cited by 335
Advances in counselling and surveillance of patients at risk for pancreatic cancer: Table 1
Brand, R. E., Lerch, M. M., Rubinstein, W. S., Neoptolemos, J. P., Whitcomb, D. C., Hruban, R. H., Brentnall, T. A., Lynch, H. T., & Canto, M. I. (2007) · Gut · doi:10.1136/gut.2006.108456 · Cited by 323
Characterization of BRCA1 and BRCA2 Mutations in a Large United States Sample
Chen, S., Iversen, E. S., Friebel, T., Finkelstein, D., Weber, B. L., Eisen, A., Peterson, L. E., Schildkraut, J. M., Isaacs, C., Peshkin, B. N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6772 · Cited by 317
Weischer, M., Bojesen, S. E., Ellervik, C., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5922 · Cited by 306
Mortality and Cancer Incidence in 263 Patients With Ataxia-Telangiectasia 2
(1986) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/77.1.89 · Cited by 305
Keller, G., Vogelsang, H., Becker, I., Hutter, J., Ott, K., Candidus, S., Grundei, T., Becker, K.-F., Mueller, J., Siewert, J. R., et al. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65129-2 · Cited by 287
PALB2 mutations in European familial pancreatic cancer families
Slater, E., Langer, P., Niemczyk, E., Strauch, K., Butler, J., Habbe, N., Neoptolemos, J., Greenhalf, W., & Bartsch, D. (2010) · Clinical Genetics · doi:10.1111/j.1399-0004.2010.01425.x · Cited by 278 · cited 2×
“Mutations in PALB2 were also detected in European families and, interestingly, each of these had also a history of breast cancer [83].”
Relative frequency and morphology of cancers in STK11 mutation carriers1 ☆
Lim, W., Olschwang, S., Keller, J. J., Westerman, A. M., Menko, F. H., Boardman, L. A., Scott, R. J., Trimbath, J., Giardiello, F. M., & Gruber, S. B. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.03.014 · Cited by 254
Langer, P., Kann, P. H., Fendrich, V, Habbe, N., Schneider, M., Sina, M., Slater, E. P., Heverhagen, J. T., Gress, T. M., Rothmund, M., et al. (2009) · Gut · doi:10.1136/gut.2008.171611 · Cited by 249
Stracker, T. H., Usui, T., & Petrini, J. H. J. (2009) · DNA Repair · doi:10.1016/j.dnarep.2009.04.012 · Cited by 243
Contribution of Inherited Mutations in the BRCA2-Interacting Protein PALB2 to Familial Breast Cancer
Casadei, S., Norquist, B. M., Walsh, T., Stray, S., Mandell, J. B., Lee, M. K., Stamatoyannopoulos, J. A., & King, M.-C. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3958 · Cited by 240
High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients.
Jóhannesdóttir, G., Guðmundsson, J., Bergþorsson, J. Þ., Arason, A., Agnarsson, B. A., Eiríksdóttir, G., Johannsson, O. T., Borg, Å., Ingvarsson, S., Easton, D. F., et al. (1996) · PubMed · Cited by 223
ATM and breast cancer susceptibility
Ahmed, M., & Rahman, N. (2006) · Oncogene · doi:10.1038/sj.onc.1209873 · Cited by 216
RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability
Heikkinen, K. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi360 · Cited by 208 · cited 3×
“This protein complex integratesDNA repair with checkpoint signalling through the ATM, BRCA1, and CHEK2 proteins [106].”
Prediction of pathogenic mutations in patients with early-onset breast cancer by family history
Lalloo, F., Varley, J., Ellis, D., Moran, A., O'Dair, L., Pharoah, P., & Evans, D. G. R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12856-5 · Cited by 202
Lalloo, F., & Evans, D. G. (2012) · Clinical Genetics · doi:10.1111/j.1399-0004.2012.01859.x · Cited by 202
Evidence for Simultaneous Protein Interactions between Human Rad51 Paralogs
Schild, D., Lio, Y.-C., Collins, D. W., Tsomondo, T., & Chen, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001473200 · Cited by 199
Pathogenesis of adenocarcinoma in Peutz-Jeghers syndrome.
Gruber, S. B., Entius, M. M., Petersen, G. M., et al. (1998) · PubMed · Cited by 190
Rare Mutations in XRCC2 Increase the Risk of Breast Cancer
Park, D. J., Lesueur, F., Nguyen-Dumont, T., Pertesi, M., Odefrey, F., Hammet, F., Neuhausen, S. L., John, E. M., Andrulis, I. L., Terry, M. B., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.02.027 · Cited by 185
Hereditary ovarian cancer: Beyond the usual suspects
Pennington, K. P., & Swisher, E. M. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.12.415 · Cited by 182
Graziano, F., Humar, B., & Guilford, P. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg486 · Cited by 168
Bartkova, J., Tommiska, J., Oplustilova, L., Aaltonen, K., Tamminen, A., Heikkinen, T., Mistrik, M., Aittomäki, K., Blomqvist, C., Heikkilä, P., et al. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.09.007 · Cited by 158
BRCA1 and BRCA2: Chemosensitivity, Treatment Outcomes and Prognosis
Foulkes, W. D. (2006) · Familial Cancer · doi:10.1007/s10689-005-2832-5 · Cited by 147
Nijmegen Breakage Syndrome mutations and risk of breast cancer
Bogdanova, N. V., Feshchenko, S., Schürmann, P., Waltes, R., Wieland, B., Hillemanns, P., Rogov, Y., Dammann, O., Bremer, M., Karstens, J. H., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.23168 · Cited by 143
RAD51C is a susceptibility gene for ovarian cancer
Pelttari, L. M., Heikkinen, T., Thompson, D. J., Kallioniemi, A. H., Schleutker, J., Holli, K., BLOMQVIST, C. P., Aittomäki, K., Bützow, R. C., & Nevanlinna, H. A. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr229 · Cited by 142
Translational advances regarding hereditary breast cancer syndromes
Gage, M. M., Wattendorf, D. J., & Henry, L. R. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.21856 · Cited by 137
A novel germline PALB2 deletion in Polish breast and ovarian cancer patients
Dansonka‐Mieszkowska, A., Kluska, A., Moes-Sosnowska, J., Dąbrowska, M., Nowakowska, D., Niwińska, A., Derlatka, P., Cendrowski, K., & Kupryjańczyk, J. (2010) · BMC Medical Genetics · doi:10.1186/1471-2350-11-20 · Cited by 123
Heikkinen, K., Karppinen, S., Soini, Y., Mäkinen, M., & Winqvist, R. (2003) · Journal of Medical Genetics · doi:10.1136/jmg.40.12.e131 · Cited by 121
A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland
Cybulski, C., Wokołorczyk, D., Huzarski, T., Byrski, T., Gronwald, J., Górski, B., Dębniak, T., Masojć, B., Jakubowska, A., van de Wetering, T., et al. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9320-y · Cited by 113
Fostira, F., Tsitlaidou, M., PAPADIMITRIOU, C. A., Pertesi, M., Timotheadou, E. T., Stavropoulou, A. V., Glentis, S., Bournakis, E., Bobos, M., Pectasides, D. G., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2021-9 · Cited by 110
Self-citationGhimenti, C., Sensi, E., Presciuttini, S., Brunetti, I. M., Conte, P., Bevilacqua, G., & Caligo, M. A. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.1223 · Cited by 110
Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance
Kluijt, I., Sijmons, R. H., Hoogerbrugge, N., Plukker, J. T. M., de Jong, D., van Krieken, J. H., van Hillegersberg, R., Ligtenberg, M. J. L., Bleiker, E. M. A., & Cats, A. (2012) · Familial Cancer · doi:10.1007/s10689-012-9521-y · Cited by 106
Osório, A., Endt, D., Fernández, F., Eirich, K., de la Hoya, M., Schmutzler, R. K., Caldés, T., Meindl, A., Schindler, D., & Benitez, J. J. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds115 · Cited by 99
BRCA2 T2722R Is a Deleterious Allele That Causes Exon Skipping
Fackenthal, J. D., Cartegni, L., Krainer, A. R., & Olopade, O. I. (2002) · The American Journal of Human Genetics · doi:10.1086/342192 · Cited by 98
Cancer Risk of Heterozygotes With the NBN Founder Mutation
Seemanová, E., Jarolı́m, P., Seeman, P., Varon, R., Digweed, M., Swift, M., & Sperling, K. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm251 · Cited by 96
Cancer predisposing BARD1 mutations in breast–ovarian cancer families
Ratajska, M., Antoszewska, E., Piskorz, A., Brożek, I., Borg, Å., Kusmierek, H., Biernat, W., & Limon, J. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1403-8 · Cited by 96
Milne, R. L., Gaudet, M. M., Spurdle, A. B., Fasching, P. A., Couch, F. J., Benitez, J. J., Pérez, J. I. A., Zamora, M. P., Malats, N., dos‐Santos‐Silva, I., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2797 · Cited by 94
Suriano, G., Oliveira, M. J., Huntsman, D., Mateus, A. R., Ferreira, P., Casares, F., Oliveira, C., Carneiro, F., Machado, J. C., Mareel, M., et al. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg316 · Cited by 90
Nseir, S., Pompéo, C. D., Soubrier, S., Lenci, H., Delour, P., Onimus, T., Saulnier, F., Mathieu, D., & Durocher, A. (2005) · Critical Care · doi:10.1186/cc3508 · Cited by 88
Seemanová, E. (1990) · Mutation Research/Reviews in Genetic Toxicology · doi:10.1016/0165-1110(90)90024-6 · Cited by 86
Rare germline mutations inPALB2and breast cancer risk: A population-based study
Tischkowitz, M. D., Capanu, M., Sabbaghian, N., Li, L., Liang, X., Vallée, M., Tavtigian, S. V., CONCANNON, P. J., Foulkes, W. D., Bernstein, L., et al. (2012) · Human Mutation · doi:10.1002/humu.22022 · Cited by 86
Response to DNA damage of CHEK2 missense mutations in familial breast cancer
Roeb, W., Higgins, J., & King, M. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds101 · Cited by 82
CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women
Adank, M. A., Jonker, M. A., Kluijt, I., van Mil, S. E., Oldenburg, R. A., Mooi, W. J., Hogervorst, F. B. L., van den Ouweland, A. M. W., Gille, J. J. P., Schmidt, M. K., et al. (2011) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2011-100380 · Cited by 76
The importance of XRCC2 in RAD51-related DNA damage repair
Tambini, C. E., Spink, K. G., Ross, C. J., Hill, M. A., & Thacker, J. (2010) · DNA repair · doi:10.1016/j.dnarep.2010.01.016 · Cited by 71
Regular surveillance for Li-fraumeni syndrome: advice, adherence and perceived benefits
Lammens, C. R. M., Bleiker, E. M. A., Aaronson, N. K., Wagner, A., Sijmons, R. H., Ausems, M. G. E. M., Vriends, A. H. J. T., Ruijs, M., van Os, T. A. M., Spruijt, L., et al. (2010) · Familial Cancer · doi:10.1007/s10689-010-9368-z · Cited by 70
Solyom, S., Aressy, B., Pylkäs, K., Patterson-Fortin, J., Hartikainen, J. M., Kallioniemi, A., Kauppila, S., Nikkilä, J., Kosma, V.-M., Mannermaa, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003223 · Cited by 59 · cited 1×
“The missense allele segregatedwith the disease in the two families, while no Abraxas genetic alterations were identified in the healthy controls studied [117].”
A role for XRCC2 gene polymorphisms in breast cancer risk and survival
Lin, W., Camp, N. J., Cannon‐Albright, L., Allen‐Brady, K., Balasubramanian, S. P., Reed, M., Hopper, J. L., Apicella, C., Giles, G. G., Southey, M. C., et al. (2011) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2011-100018 · Cited by 59
Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families
Osher, D. J., Leeneer, K. D., Michils, G., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.87 · Cited by 52
The WECARE Study Collaborative Group, Mellemkjær, L., Dahl, C., Olsen, J. H., Bertelsen, L., Guldberg, P., Christensen, J., Børresen-Dale, A.-L., Stovall, M. A., Langholz, B. M., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604228 · Cited by 51
Pelttari, L. M., Kiiski, J. I., Nurminen, R., Kallioniemi, A. H., Schleutker, J., Gylfe, A. E., Aaltonen, L. A., Leminen, A., Heikkilä, P., BLOMQVIST, C. P., et al. (2012) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2012-100852 · Cited by 49
Birch, J. M., Heighway, J., Teare, M. D., Kelsey, A. M., Hartley, A. L., Tricker, K. J., Crowther, D., Lane, D. P., & Santibanez‐Koref, M. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.468 · Cited by 49
Rare variants in XRCC2 as breast cancer susceptibility alleles: Table 1
Hilbers, F., Wijnen, J., Hoogerbrugge, N., Oosterwijk, J. C., Collee, M. J., Peterlongo, P., Radice, P., Manoukian, S., Feroce, I., Capra, F., et al. (2012) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2012-101191 · Cited by 47
Genetic Counseling and Testing for Common Hereditary Breast Cancer Syndromes
Allain, D. C. (2008) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.070161 · Cited by 46
Eng, C. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04337.x · Cited by 44
Konstantopoulou, I., Rampias, T., Ladopoulou, A., Koutsodontis, G., Armaou, S., Anagnostopoulos, T., Nikolopoulos, G., Kamakari, S., Nounesis, G., Stylianakis, A., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9571-2 · Cited by 43
Desjardins, S., Beauparlant, J. C., Labrie, Y., Ouellette, G., BRCAs, I., & Durocher, F. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-181 · Cited by 40
Cybulski, C., Górski, B., Huzarski, T., Byrski, T., Gronwald, J., Dębniak, T., Wokołorczyk, D., Jakubowska, A., Serrano‐Fernández, P., Dörk, T., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2008.061697 · Cited by 33
Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families
Catucci, I., Milgrom, R., Kushnir, A., Laitman, Y., Paluch–Shimon, S., Volorio, S., Ficarazzi, F., Bernard, L., Radice, P., Friedman, E., et al. (2012) · Familial Cancer · doi:10.1007/s10689-012-9540-8 · Cited by 32
Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes
Menéndez, M., Castellsagué, J., Mirete, M., Pros, E., Feliubadaló, L., Osório, A., Calaf, M., Tornero, E., Valle, J. D., Fernández‐Rodríguez, J., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1661-5 · Cited by 24
Cited by
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017
Daly, M. B., Pilarski, R., Berry, M., Buys, S. S., Farmer, M., Friedman, S., Garber, J. E., Kauff, N. D., Khan, S., Klein, C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0003 · Cited by 650
The evolution of cancer surgery and future perspectives
Wyld, L., Audisio, R. A., & Poston, G. J. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.191 · Cited by 430
Taglialatela, A., Alvarez, S., Leuzzi, G., Sannino, V., Ranjha, L., Huang, J.-W., Madubata, C., Anand, R., Levy, B., Rabadan, R., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.09.036 · Cited by 394
Aluminium and the human breast
Darbre, P. D. (2016) · Morphologie · doi:10.1016/j.morpho.2016.02.001 · Cited by 78
Metadata
- Authors
- Apostolou, P., & Fostira, F.
- Venue
- BioMed Research International
- Publisher
- Hindawi Limited
- Published
- 2013
- Volume
- 2013
- Pages
- 1-11
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- OpenAlex
- W2000870557
- Cited by
- 351
- References
- 123
- FWCI
- 13.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.